每经AI快讯，10月17日，片仔癀（600436）(600436.SH)公告称，公司研发的1.1类中药创新药温胆片已 完成Ⅲ期临床试验首例受试者入组，正式进入Ⅲ期临床试验。温胆片适应症为轻、中度广泛性焦虑障碍 (痰热内扰证)。 ...

新京报贝壳财经讯 10月17日，企查查APP显示，近日，广生合癀（漳州）医药有限公司成立，法定代 表人为黄晓航，注册资本为5000万元，经营范围包含：药品批发；第三类医疗器械经营；食品销售；保 健食品（预包装）销售；食品互联网销售（仅销售预包装食品）等。企查查股权穿透显示，该公司由广 生堂、片仔癀全资子公司福建片仔癀健康科技有限公司共同持股。 ...

Core Viewpoint - Guangsheng Hehuang (Zhangzhou) Pharmaceutical Co., Ltd. has been established with a registered capital of 50 million yuan, indicating a strategic move in the pharmaceutical and healthcare sector [1] Company Summary - The legal representative of the newly established company is Huang Xiaohang [1] - The company's business scope includes drug wholesale, third-class medical device operation, food sales, health food (pre-packaged) sales, and online sales of pre-packaged food [1] - The company is jointly owned by Guangsheng Tang and Fujian Pianzaihuang Health Technology Co., Ltd., a wholly-owned subsidiary of Pianzaihuang [1]

Core Viewpoint - Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. announced its participation in the CICC Medical Fund, focusing on investments in the healthcare sector, particularly in traditional Chinese medicine, biomedicine, medical devices, and related industries [1] Group 1 - The CICC Medical Fund aims to raise a total of 1 billion RMB, with Zhangzhou Pien Tze Huang Investment Management Co., Ltd. committing to invest 200 million RMB, representing 20% of the fund's target size [1] - The fund will primarily invest in projects related to the Pien Tze Huang industry chain, Pien Tze Huang industrial park, and other projects that attract investment to Zhangzhou [1] - The investment strategy aligns with the growing trend in the healthcare sector, emphasizing the importance of traditional Chinese medicine and related health services [1]

Core Insights - A new company, Guangsheng Hehuang (Zhangzhou) Pharmaceutical Co., Ltd., has been established with a registered capital of 50 million yuan [1] - The company's business scope includes drug wholesale, food sales, health food sales, and online food sales [1] - The ownership structure shows that Guangsheng Tang holds 51% and Fujian Pianzaihuang Health Technology Co., Ltd. holds 49% [1]

Core Viewpoint - Recently, a new investment partnership named Zhongjin (Zhangzhou) Medical Industry Investment Partnership (Limited Partnership) was established with a capital of 1 billion yuan, focusing on investment activities using its own funds [1] Group 1: Company Information - The new partnership is co-funded by Pianzaihuang's wholly-owned subsidiary Zhangzhou Pianzaihuang Investment Management Co., Ltd. and Zhongjin Company's wholly-owned subsidiary Zhongjin Capital Operation Co., Ltd. [1]

Core Insights - The Medical Health Index (980016) closed at 6759.45 points, up 1.78%, with a trading volume of 27.946 billion yuan and a turnover rate of 1.0% [1] - Among the index constituents, 40 stocks rose, with Huahai Pharmaceutical leading at a 7.59% increase, while 9 stocks fell, with BGI Genomics leading the decline at 2.93% [1] Index Performance - The Medical Health Index saw a net inflow of 1.063 billion yuan from main funds, while retail investors experienced a net outflow of 392 million yuan [1] - The top ten constituents of the index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with varying market capitalizations and price changes [1] Fund Flow Analysis - Huahai Pharmaceutical had a main fund net inflow of 163 million yuan, while retail investors saw a net outflow of 76.6 million yuan [2] - Other notable companies with significant fund flows include Aier Eye Hospital and Hengrui Medicine, both experiencing mixed inflows and outflows from different investor categories [2]

Core Viewpoint - CICC (Zhangzhou) Medical Industry Investment Partnership has been established with a capital contribution of 1 billion yuan, focusing on investment activities using its own funds [1]. Group 1: Company Information - The partnership is a limited partnership formed by Zhangzhou Pianzaihuang Investment Management Co., Ltd., a wholly-owned subsidiary of Pianzaihuang, and CICC Capital Operation Co., Ltd., a wholly-owned subsidiary of CICC [1]. - The registered capital of the partnership is 1 billion yuan, and it is located in Longhai District, Zhangzhou City, Fujian Province [2]. - The partnership's business scope includes general investment activities using self-owned funds, excluding projects that require approval [2]. Group 2: Partnership Structure - The partnership includes several contributors, with Zhangzhou Pianzaihuang Investment Management Co., Ltd. holding a 20% stake [3]. - Other partners include Zhangzhou Pianzaihuang Pharmaceutical Co., Ltd. (100% ownership), Zhangzhou Pianzaihuang Asset Management Co., Ltd. (20%), and Zhangzhou Gaoxin Development Co., Ltd. (20%) [3]. - CICC Capital Operation Co., Ltd. serves as the executive partner and is classified as a private equity fund manager [3].

Core Viewpoint - The establishment of the CICC (Zhangzhou) Medical Industry Investment Partnership marks a significant investment initiative in the healthcare sector, focusing on traditional Chinese medicine and related industries [1] Group 1: Company Information - CICC (Zhangzhou) Medical Industry Investment Partnership has been established with a total investment of 1 billion RMB, managed by CICC Capital Operation Co., Ltd [1] - The partnership includes contributions from Zhangzhou Gaoxin Development Co., Ltd, Zhangzhou Pien Tze Huang Asset Management Co., Ltd, Zhangzhou Industrial Equity Investment Co., Ltd, and CICC Capital Operation Co., Ltd [1] Group 2: Investment Focus - The primary investment focus of the fund is on the healthcare sector, specifically in areas such as traditional Chinese medicine, biomedicine, medical devices, medical services, daily chemical beauty products, and health and wellness [1] - The fund will also consider projects related to the Pien Tze Huang industry chain, the Pien Tze Huang industrial park, and projects that attract investment to Zhangzhou [1] Group 3: Financial Commitment - Pien Tze Huang's wholly-owned subsidiary, Zhangzhou Pien Tze Huang Investment Management Co., Ltd, plans to invest 200 million RMB as a limited partner, representing 20% of the target fundraising scale of the CICC Medical Fund [1]

天眼查工商信息显示，近日，广生合癀（漳州）医药有限公司成立，法定代表人为黄晓航，注册资本 5000万人民币，经营范围含药品批发、食品销售、保健食品销售、食品互联网销售、特殊医学用途配方 食品销售、化妆品批发、日用杂品销售、以自有资金从事投资活动等。股东信息显示，该公司由广生堂 以及片仔癀旗下福建片仔癀健康科技有限公司分别持股51%、49%。 ...